Azacitidine is approved for the treatment of patients with the myelodysplastic syndrome subtypes, including refractory anemia or chronic leukemia.
The is around 5,022 INR for the supply of a single vial.
It belongs to the group of drugs named metabolites, which interferes with the growth of cancerous cells. Since the growth of normal body cells may also be affected due to it, other effects may also occur. Some of these may be severe and must be reported to a healthcare practitioner. Azacitidine is to be administered only by or under the direct supervision of a healthcare professional.